Identification

Name
Furosemide
Accession Number
DB00695  (APRD00608, DB07799)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]

Structure
Thumb
Synonyms
  • 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
  • 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
  • 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
  • 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
  • Frusemide
  • Furosemid
  • Furosemida
  • Furosemide
  • Furosemidu
  • Furosemidum
  • Lasix (tn)
External IDs
LB-502 / NSC-269420
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-furosemideTablet40 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet80 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet20 mgOralAvanstra Inc2011-08-112014-08-21Canada
Bio-furosemideTablet20 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-furosemideTablet40 mgOralBiomed Pharma2003-04-11Not applicableCanada
Dom-furosemideTablet20 mgOralBiomed Pharma2003-10-142013-08-02Canada
Dom-furosemideTablet40 mgOralBiomed Pharma2003-10-142013-08-02Canada
FuosemideTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-10Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-08-012017-01-25Us
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2013-11-19Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Furosemide Tab 20mgTablet20 mgOralApotex Corporation1977-12-31Not applicableCanada
Apo Furosemide Tab 40mgTablet40 mgOralApotex Corporation1976-12-31Not applicableCanada
Apo Furosemide Tab 80mgTablet80 mgOralApotex Corporation1986-12-31Not applicableCanada
Diascreen 12-Panel Medicated Collection SystemKitIt3 Medical Llc2016-07-27Not applicableUs
FurosemideTablet80 mg/1OralMylan Pharmaceuticals1986-10-29Not applicableUs00378 0232 01 nlmimage10 86204302
FurosemideTablet20 mg/1OralRemedy Repack2010-11-012015-12-29Us
FurosemideTablet80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1991-03-13Not applicableUs
FurosemideTablet40 mg/1OralA S Medication Solutions2004-03-262017-06-20Us
FurosemideTablet40 mg/1OralRanbaxy Inc.2009-01-29Not applicableUs
FurosemideTablet80 mg/1OralLeading Pharma, Llc2006-02-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FurosemideTablet40 mg/1OralRemedy Repack2017-10-27Not applicableUs
FurosemideTablet20 mg/1OralRemedy Repack2017-11-10Not applicableUs
International/Other Brands
Diurapid (Mibe Jena) / Diurin (Mylan) / Diurmessel (Biomep) / Eutensin (Sanofi) / Frumex / Frusenex / Frusol (Rosemont) / Furo-Puren (Actavis) / Seguril (Sanofi)
Categories
UNII
7LXU5N7ZO5
CAS number
54-31-9
Weight
Average: 330.744
Monoisotopic: 330.007719869
Chemical Formula
C12H11ClN2O5S
InChI Key
ZZUFCTLCJUWOSV-UHFFFAOYSA-N
InChI
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
IUPAC Name
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.

Structured Indications
Pharmacodynamics

Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome.

Mechanism of action

Furosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
UCarbonic anhydrase 2Not AvailableHuman
Absorption

60% absorbed in patients with normal renal function

Volume of distribution
Not Available
Protein binding

95% bound to plasma proteins

Metabolism

Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.

Route of elimination

Furosemide is excreted in urine. Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution.

Half life

2 hours

Clearance
Not Available
Toxicity

Profound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Furosemide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Furosemide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Furosemide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Furosemide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the diuretic activities of Furosemide.Approved, Investigational
AcemetacinAcemetacin may decrease the diuretic activities of Furosemide.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Furosemide.Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Furosemide.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Furosemide.Experimental, Investigational
AlclofenacAlclofenac may decrease the diuretic activities of Furosemide.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Furosemide.Approved
AlcuroniumFurosemide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Furosemide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide.Approved, Illicit
AliskirenThe serum concentration of Furosemide can be decreased when it is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Furosemide.Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Furosemide is combined with Allopurinol.Approved
AlminoprofenAlminoprofen may decrease the diuretic activities of Furosemide.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Furosemide.Approved
AloxiprinAloxiprin may decrease the diuretic activities of Furosemide.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Furosemide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Furosemide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Furosemide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Furosemide.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Furosemide is combined with Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Furosemide.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Furosemide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Furosemide.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Furosemide.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Furosemide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Furosemide.Approved, Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Furosemide is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the diuretic activities of Furosemide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Furosemide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Furosemide.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Furosemide.Investigational
annamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Furosemide.Approved
ApocyninApocynin may decrease the diuretic activities of Furosemide.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Furosemide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Apraclonidine.Approved
ApramycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Furosemide.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Furosemide is combined with Arbekacin.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Furosemide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Furosemide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Furosemide.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Furosemide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Furosemide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Furosemide.Approved
AtracuriumFurosemide may decrease the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateFurosemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Furosemide.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Furosemide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Furosemide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Furosemide.Investigational
BalsalazideBalsalazide may decrease the diuretic activities of Furosemide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Furosemide.Experimental
BarbitalBarbital may increase the hypotensive activities of Furosemide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Furosemide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Furosemide.Approved, Investigational
BekanamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Bekanamycin.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Furosemide.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Furosemide.Approved, Investigational
BendazacBendazac may decrease the diuretic activities of Furosemide.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Furosemide.Approved
BenorilateBenorilate may decrease the diuretic activities of Furosemide.Experimental
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Furosemide.Withdrawn
BenzydamineBenzydamine may decrease the diuretic activities of Furosemide.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Furosemide.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Furosemide.Approved
BevoniumBevonium may decrease the diuretic activities of Furosemide.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Furosemide.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Furosemide.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Furosemide.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Furosemide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Furosemide.Approved
BromfenacBromfenac may decrease the diuretic activities of Furosemide.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Furosemide.Approved, Investigational
BucillamineBucillamine may decrease the diuretic activities of Furosemide.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Furosemide.Approved
BufexamacBufexamac may decrease the diuretic activities of Furosemide.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Furosemide.Investigational, Withdrawn
BumadizoneBumadizone may decrease the diuretic activities of Furosemide.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Furosemide.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furosemide.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Furosemide.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Furosemide is combined with Candesartan cilexetil.Approved
CandoxatrilFurosemide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Captopril.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the diuretic activities of Furosemide.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Furosemide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Furosemide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Furosemide.Illicit, Investigational, Vet Approved
CarprofenCarprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Furosemide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Furosemide is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the diuretic activities of Furosemide.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Furosemide.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Furosemide.Approved, Investigational
Chloral hydrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloroquineChloroquine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Furosemide.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Furosemide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Furosemide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the diuretic activities of Furosemide.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Furosemide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Furosemide.Approved, Investigational
CisatracuriumFurosemide may decrease the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateFurosemide may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinFurosemide may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Furosemide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Furosemide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Furosemide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Furosemide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Furosemide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Furosemide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Furosemide.Approved
ClonixinClonixin may decrease the diuretic activities of Furosemide.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Furosemide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Furosemide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Furosemide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Furosemide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Furosemide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Furosemide.Approved
CurcuminCurcumin may decrease the diuretic activities of Furosemide.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Furosemide is combined with Cymarin.Experimental
D-LimoneneD-Limonene may decrease the diuretic activities of Furosemide.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Furosemide is combined with Dapagliflozin.Approved
DaunorubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Daunorubicin.Approved
DecamethoniumFurosemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Furosemide.Approved
DelaprilFurosemide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Furosemide.Investigational
dersalazinedersalazine may decrease the diuretic activities of Furosemide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Furosemide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Furosemide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Furosemide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Furosemide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Furosemide.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Furosemide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Furosemide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Furosemide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Furosemide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Furosemide.Approved, Investigational
DibekacinThe risk or severity of adverse effects can be increased when Furosemide is combined with Dibekacin.Experimental
DiclofenacDiclofenac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Diclofenamide.Approved
DifenpiramideDifenpiramide may decrease the diuretic activities of Furosemide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Furosemide.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Furosemide.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Furosemide.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Furosemide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furosemide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Furosemide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furosemide.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Furosemide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Furosemide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Furosemide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Furosemide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Furosemide.Approved
DofetilideFurosemide may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidFurosemide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideFurosemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Furosemide.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Furosemide.Investigational
DroxicamDroxicam may decrease the diuretic activities of Furosemide.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Furosemide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Furosemide.Approved
DuloxetineFurosemide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the diuretic activities of Furosemide.Investigational
E-6201E-6201 may decrease the diuretic activities of Furosemide.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Furosemide.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Furosemide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Furosemide.Approved, Vet Approved
EnalaprilatFurosemide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Furosemide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Furosemide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Furosemide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Furosemide.Experimental
EquilinEquilin may increase the hypokalemic activities of Furosemide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Furosemide.Approved
EstroneEstrone may increase the hypokalemic activities of Furosemide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Furosemide.Approved
Etacrynic acidFurosemide may increase the ototoxic activities of Etacrynic acid.Approved
EtanerceptEtanercept may decrease the diuretic activities of Furosemide.Approved, Investigational
EthenzamideEthenzamide may decrease the diuretic activities of Furosemide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Furosemide.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Furosemide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Furosemide.Approved, Investigational
EtoricoxibEtoricoxib may decrease the diuretic activities of Furosemide.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Furosemide.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Furosemide.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Furosemide.Approved, Investigational
exisulindexisulind may decrease the diuretic activities of Furosemide.Investigational
FelbinacFelbinac may decrease the diuretic activities of Furosemide.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the diuretic activities of Furosemide.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Furosemide.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Furosemide.Approved
FenoterolFenoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the diuretic activities of Furosemide.Experimental
FeprazoneFeprazone may decrease the diuretic activities of Furosemide.Experimental
Ferulic acidFerulic acid may decrease the diuretic activities of Furosemide.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Furosemide.Approved, Investigational
FloctafenineFloctafenine may decrease the diuretic activities of Furosemide.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Furosemide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Furosemide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Furosemide.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Furosemide.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the diuretic activities of Furosemide.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Furosemide.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Furosemide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Furosemide.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Furosemide.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Furosemide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Furosemide.Approved
FormestaneFormestane may increase the hypokalemic activities of Furosemide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Furosemide.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Furosemide.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Furosemide.Approved
FramycetinThe risk or severity of adverse effects can be increased when Furosemide is combined with Framycetin.Approved
GallamineFurosemide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideFurosemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe risk or severity of adverse effects can be increased when Furosemide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Furosemide is combined with GENTAMICIN C1A.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Furosemide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Furosemide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Furosemide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Furosemide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Furosemide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Furosemide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Furosemide.Approved
GPX-150The risk or severity of adverse effects can be increased when Furosemide is combined with GPX-150.Investigational
GuacetisalGuacetisal may decrease the diuretic activities of Furosemide.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Furosemide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Furosemide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Furosemide.Approved, Investigational, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Furosemide.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Furosemide.Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the diuretic activities of Furosemide.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Furosemide.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Furosemide.Approved
HigenamineHigenamine may decrease the diuretic activities of Furosemide.Investigational
HyaluronidaseThe therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Furosemide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Furosemide is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Furosemide.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Furosemide.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Furosemide.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Idarubicin.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Furosemide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Furosemide.Investigational
Imidazole salicylateImidazole salicylate may decrease the diuretic activities of Furosemide.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Furosemide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Furosemide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Indapamide.Approved
IndobufenIndobufen may decrease the diuretic activities of Furosemide.Investigational
IndomethacinIndomethacin may decrease the diuretic activities of Furosemide.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Furosemide.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Furosemide.Withdrawn
INNO-206The risk or severity of adverse effects can be increased when Furosemide is combined with INNO-206.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Furosemide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Furosemide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Furosemide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Furosemide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Furosemide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Furosemide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Furosemide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Irbesartan.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Furosemide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Furosemide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Furosemide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Furosemide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Furosemide.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Furosemide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Furosemide.Investigational
IvabradineFurosemide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Furosemide.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Furosemide.Approved, Investigational
KetoprofenKetoprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Furosemide.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Furosemide.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Furosemide.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Furosemide is combined with Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the diuretic activities of Furosemide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Furosemide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Furosemide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Furosemide.Approved, Investigational
LevodopaFurosemide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furosemide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furosemide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Furosemide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Furosemide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Furosemide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Furosemide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Furosemide.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Furosemide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Furosemide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Furosemide.Approved, Investigational
LonazolacLonazolac may decrease the diuretic activities of Furosemide.Experimental
LornoxicamLornoxicam may decrease the diuretic activities of Furosemide.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Furosemide.Approved
LoxoprofenLoxoprofen may decrease the diuretic activities of Furosemide.Approved, Investigational
LumiracoxibLumiracoxib may decrease the diuretic activities of Furosemide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Furosemide.Approved
MannitolThe risk or severity of adverse effects can be increased when Furosemide is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the diuretic activities of Furosemide.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Furosemide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Furosemide.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Furosemide.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Furosemide.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Furosemide.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Furosemide.Experimental
MesalazineMesalazine may decrease the diuretic activities of Furosemide.Approved
MetamizoleMetamizole may decrease the diuretic activities of Furosemide.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Furosemide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Furosemide.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Furosemide.Approved
MethotrexateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Furosemide.Approved
Methyl salicylateMethyl salicylate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Furosemide is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Furosemide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Furosemide is combined with Metipranolol.Approved
MetocurineFurosemide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideFurosemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Furosemide.Approved, Investigational
MetrizamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Metrizamide.Approved
MicronomicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Micronomicin.Experimental
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Furosemide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Furosemide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Furosemide.Approved, Investigational
MivacuriumFurosemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Furosemide.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Furosemide.Approved
MofebutazoneMofebutazone may decrease the diuretic activities of Furosemide.Experimental
MometasoneMometasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Furosemide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Furosemide.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Furosemide.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Furosemide.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Furosemide.Approved, Investigational
NabumetoneNabumetone may decrease the diuretic activities of Furosemide.Approved
NadololThe risk or severity of adverse effects can be increased when Furosemide is combined with Nadolol.Approved
NafamostatNafamostat may decrease the diuretic activities of Furosemide.Approved, Investigational
NaftifineNaftifine may decrease the diuretic activities of Furosemide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furosemide.Approved
NaproxenNaproxen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Furosemide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Furosemide.Investigational
NeamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Furosemide is combined with Nebivolol.Approved, Investigational
NeomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinFurosemide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Furosemide.Approved
NesiritideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nesiritide.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Netilmicin.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Furosemide.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Furosemide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Furosemide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Nifedipine.Approved
NifenazoneNifenazone may decrease the diuretic activities of Furosemide.Experimental
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Furosemide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Furosemide.Approved, Investigational
NimesulideNimesulide may decrease the diuretic activities of Furosemide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Furosemide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Furosemide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Furosemide.Approved
NitroaspirinNitroaspirin may decrease the diuretic activities of Furosemide.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Furosemide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Furosemide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Furosemide.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Furosemide.Approved
OleandrinThe risk or severity of adverse effects can be increased when Furosemide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Furosemide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Furosemide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Furosemide.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Furosemide.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Furosemide.Approved
OmapatrilatFurosemide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Furosemide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Furosemide.Approved
OrgoteinOrgotein may decrease the diuretic activities of Furosemide.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Furosemide is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Furosemide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Furosemide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Furosemide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furosemide.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Furosemide.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Furosemide.Approved, Vet Approved
PancuroniumFurosemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Furosemide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Furosemide.Approved
ParecoxibParecoxib may decrease the diuretic activities of Furosemide.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Paromomycin.Approved, Investigational
ParthenolideParthenolide may decrease the diuretic activities of Furosemide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Furosemide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Furosemide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Furosemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Furosemide.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Furosemide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Furosemide.Approved, Investigational, Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Furosemide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Furosemide.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Furosemide.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Furosemide.Approved
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Furosemide.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Furosemide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Furosemide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Furosemide.Approved, Investigational
PipecuroniumFurosemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Furosemide.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Furosemide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Furosemide.Investigational
PiroxicamPiroxicam may decrease the diuretic activities of Furosemide.Approved, Investigational
PirprofenPirprofen may decrease the diuretic activities of Furosemide.Experimental
PlazomicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Plazomicin.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Plicamycin.Approved, Investigational, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Furosemide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Furosemide.Approved, Investigational
PranoprofenPranoprofen may decrease the diuretic activities of Furosemide.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Furosemide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Furosemide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Furosemide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Furosemide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Furosemide.Experimental, Investigational
PrimidonePrimidone may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Furosemide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
ProglumetacinProglumetacin may decrease the diuretic activities of Furosemide.Experimental
PropacetamolPropacetamol may decrease the diuretic activities of Furosemide.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Furosemide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Furosemide.Approved, Investigational
PropyphenazonePropyphenazone may decrease the diuretic activities of Furosemide.Experimental
ProquazoneProquazone may decrease the diuretic activities of Furosemide.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Furosemide is combined with Proscillaridin.Experimental
PTC299PTC299 may decrease the diuretic activities of Furosemide.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Puromycin.Experimental
PyrantelFurosemide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Furosemide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Furosemide is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide.Approved
RapacuroniumFurosemide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Furosemide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Furosemide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Furosemide.Approved, Investigational
RescinnamineFurosemide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Furosemide.Approved, Investigational
ResveratrolResveratrol may decrease the diuretic activities of Furosemide.Approved, Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Ribostamycin.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Furosemide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Furosemide is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Furosemide.Approved, Investigational
RocuroniumFurosemide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Furosemide.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Furosemide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Furosemide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Furosemide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Furosemide.Approved
SabarubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Sabarubicin.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Furosemide.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Furosemide.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Furosemide.Approved
SalsalateSalsalate may decrease the diuretic activities of Furosemide.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Furosemide.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Furosemide.Approved, Investigational, Vet Approved
SemapimodSemapimod may decrease the diuretic activities of Furosemide.Investigational
SeratrodastSeratrodast may decrease the diuretic activities of Furosemide.Approved
SerrapeptaseSerrapeptase may decrease the diuretic activities of Furosemide.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Furosemide.Approved, Vet Approved
SisomicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Sisomicin.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Furosemide.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Furosemide.Approved
Sodium phosphateFurosemide may increase the nephrotoxic activities of Sodium phosphate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Furosemide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Furosemide.Approved
SP1049CThe risk or severity of adverse effects can be increased when Furosemide is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiraprilFurosemide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Furosemide.Approved
SRT501SRT501 may decrease the diuretic activities of Furosemide.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Furosemide.Approved, Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptozocin.Approved
SuccinylcholineFurosemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateThe serum concentration of Furosemide can be decreased when it is combined with Sucralfate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.Approved, Investigational
SulfasalazineSulfasalazine may decrease the diuretic activities of Furosemide.Approved
SulindacSulindac may decrease the diuretic activities of Furosemide.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Furosemide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.Approved, Investigational
SuprofenSuprofen may decrease the diuretic activities of Furosemide.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the diuretic activities of Furosemide.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Furosemide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide.Approved
TarenflurbilTarenflurbil may decrease the diuretic activities of Furosemide.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Telmisartan.Approved, Investigational
TemocaprilFurosemide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the diuretic activities of Furosemide.Experimental
TenoxicamTenoxicam may decrease the diuretic activities of Furosemide.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Furosemide.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Furosemide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Furosemide.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Furosemide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Furosemide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Furosemide.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Furosemide.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Furosemide.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Furosemide.Approved
TinoridineTinoridine may decrease the diuretic activities of Furosemide.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Furosemide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Tizanidine.Approved
TobramycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Tobramycin.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Furosemide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Furosemide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Furosemide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furosemide.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Furosemide.Approved
TolmetinTolmetin may decrease the diuretic activities of Furosemide.Approved
TopiramateFurosemide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Furosemide.Approved
TranilastTranilast may decrease the diuretic activities of Furosemide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Furosemide.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Furosemide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Furosemide.Approved
TribenosideTribenoside may decrease the diuretic activities of Furosemide.Experimental
TriptolideTriptolide may decrease the diuretic activities of Furosemide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Furosemide.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may decrease the diuretic activities of Furosemide.Approved
TubocurarineFurosemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Furosemide.Approved
ValdecoxibValdecoxib may decrease the diuretic activities of Furosemide.Investigational, Withdrawn
ValrubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide.Approved, Investigational
VecuroniumFurosemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Furosemide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Furosemide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Furosemide.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the diuretic activities of Furosemide.Approved, Investigational
ZileutonZileuton may decrease the diuretic activities of Furosemide.Approved, Investigational, Withdrawn
ZofenoprilFurosemide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the diuretic activities of Furosemide.Withdrawn
Zoptarelin doxorubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Zoptarelin doxorubicin.Investigational
ZorubicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Zorubicin.Experimental
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food to reduce irritation.

References

Synthesis Reference

Angelo Signor, Alfredo Guerrato, Giovanni Signor, "Process for the preparation of furosemide." U.S. Patent US5739361, issued June, 1971.

US5739361
General References
  1. Rais-Bahrami K, Majd M, Veszelovszky E, Short BL: Use of furosemide and hearing loss in neonatal intensive care survivors. Am J Perinatol. 2004 Aug;21(6):329-32. [PubMed:15311369]
  2. Korpi ER, Kuner T, Seeburg PH, Luddens H: Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol. 1995 Feb;47(2):283-9. [PubMed:7870036]
  3. Tia S, Wang JF, Kotchabhakdi N, Vicini S: Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit. J Neurosci. 1996 Jun 1;16(11):3630-40. [PubMed:8642407]
  4. Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ: Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Mol Pharmacol. 1996 Sep;50(3):670-8. [PubMed:8794909]
External Links
Human Metabolome Database
HMDB01933
KEGG Drug
D00331
KEGG Compound
C07017
PubChem Compound
3440
PubChem Substance
46506779
ChemSpider
3322
BindingDB
25902
ChEBI
47426
ChEMBL
CHEMBL35
Therapeutic Targets Database
DAP000043
PharmGKB
PA449719
HET
FUN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Furosemide
ATC Codes
C03EB01 — Furosemide and potassium-sparing agentsC03CB01 — Furosemide and potassiumC03CA01 — FurosemideG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 40:28.08 — Loop Diuretics
PDB Entries
1z9y / 2xn5 / 3rf4
FDA label
Download (462 KB)
MSDS
Download (74.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentAcute Kidney Injury (AKI)1
0RecruitingPreventionTransfusion-associated Circulatory Overload1
1CompletedBasic ScienceDrug Drug Interactions1
1CompletedBasic ScienceDyspnea1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of Ipragliflozin1
1CompletedBasic ScienceRenal Hemodynamics1
1CompletedTreatmentDiabetes / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentRenal Failure1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Not Yet RecruitingBasic ScienceMedication Absorption1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentAcute Heart Failure (AHF)1
1RecruitingTreatmentCongestive Heart Failure (CHF) / Prophylaxis of cardiomyopathy1
1RecruitingTreatmentDifficulty Breathing1
1TerminatedTreatmentHeart Failure, Unspecified / Impaired Renal Function1
1, 2Active Not RecruitingBasic ScienceDyspnea / Healthy Volunteers1
1, 2Active Not RecruitingSupportive CareDyspnea1
1, 2CompletedTreatmentHeart Failure, Unspecified1
1, 2CompletedTreatmentHeart Failure, Unspecified / Renal Function Abnormal1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2WithdrawnTreatmentAcute Decompensated Heart Failure (ADHF)1
2CompletedTreatmentAscites / Liver Cirrhosis1
2CompletedTreatmentBronchiolitis1
2CompletedTreatmentCutaneous Warts1
2CompletedTreatmentHeart Failure, Unspecified1
2CompletedTreatmentTransient Tachypnoea of the Newborn1
2Not Yet RecruitingTreatmentAcute Heart Failure (AHF) / Decompensated Heart Failure1
2RecruitingOtherChronic Lung Disease of Prematurity1
2RecruitingPreventionHypertensive1
2WithdrawnTreatmentDelayed Graft Function1
2, 3CompletedTreatmentCongestive Heart Failure (CHF)1
2, 3CompletedTreatmentHeart Failure, Unspecified2
2, 3Not Yet RecruitingHealth Services ResearchAcute Heart Failure (AHF)1
2, 3TerminatedTreatmentAcute Renal Failure (ARF)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedSupportive CareBronchiolitis1
3CompletedTreatmentCongestive Heart Failure (CHF) / Impaired Renal Function1
3CompletedTreatmentFluid Overload1
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentTransient Tachypnea of the Newborn1
3Not Yet RecruitingTreatmentAcute Myocardial Infarction With Right Ventricular Extension1
3RecruitingDiagnosticChronic Kidney Disease (CKD)1
3RecruitingTreatmentCutaneous Common Warts1
3RecruitingTreatmentFluid Balance of ICU Patients / Fluid Overload1
3RecruitingTreatmentHeart Failure, Unspecified1
3SuspendedTreatmentCongestive Heart Failure (CHF)1
3TerminatedTreatmentCritically Ill / Renal Failure1
3Unknown StatusPreventionContrast Induced Nephropathy (CIN)1
3Unknown StatusTreatmentChronic Lung Diseases1
3WithdrawnTreatmentHeart Failure, Unspecified1
3WithdrawnTreatmentRenal Function Disorder1
4Active Not RecruitingTreatmentAcute Heart Failure (AHF)1
4Active Not RecruitingTreatmentHeart Failure, Diastolic1
4CompletedPreventionArterial Hypotension / Congestive Heart Failure (CHF) / Edema / Hypertensive1
4CompletedTreatmentAcute Decompensated Heart Failure (ADHF)1
4CompletedTreatmentAscites / Liver Cirrhosis2
4CompletedTreatmentChronic Heart Failure (CHF) / Congestive Heart Failure (CHF)1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4CompletedTreatmentChronic Stable Heart Failure2
4CompletedTreatmentColorectal Disorders1
4CompletedTreatmentCongestive Heart Failure (CHF)2
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
4CompletedTreatmentEdema / Glomerulonephritis minimal lesion1
4CompletedTreatmentPreeclampsia1
4Not Yet RecruitingOtherCystoscopy1
4Not Yet RecruitingTreatmentAcute Heart Failure (AHF)1
4Not Yet RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingDiagnosticEnd Stage Renal Disease (ESRD)1
4RecruitingTreatmentHeart Failure, Unspecified2
4RecruitingTreatmentHypertension Resistant To Conventional Therapy1
4RecruitingTreatmentProteinuria / Renal Insufficiency,Chronic1
4RecruitingTreatmentProphylaxis of Pulmonary embolism1
4TerminatedTreatmentAcute Decompensated Heart Failure (ADHF)1
4TerminatedTreatmentAcute Kidney Injury (AKI) / Critical Illness / Fluid Overload1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentAcute Heart Failure (AHF)1
4Unknown StatusTreatmentChronic Kidney Insufficiency / Diuresis Preserved / Hemodialysis Treatment1
4Unknown StatusTreatmentHealthy Male and Female Volunteers1
4WithdrawnTreatmentKidney Failures, Acute1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedDiagnosticCardiorenal Syndrome1
Not AvailableCompletedDiagnosticChronic Kidney Disease (CKD)1
Not AvailableCompletedPreventionAcute Renal Failure (ARF)1
Not AvailableCompletedTreatmentAcromegaly1
Not AvailableCompletedTreatmentAcute Kidney Injury (AKI)1
Not AvailableCompletedTreatmentFluid Over-load1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableNot Yet RecruitingTreatmentHeart Decompensation1
Not AvailableRecruitingNot AvailableAcidosis, Renal Tubular / Calcium Nephrolithiasis / Vacuolar Proton-Translocating ATPases1
Not AvailableRecruitingDiagnosticAcute Renal Failure (ARF)1
Not AvailableRecruitingDiagnosticCritical Illness / Oliguria1
Not AvailableRecruitingDiagnosticDelayed Graft Function / Kidney Function / Kidney Transplant; Complications1
Not AvailableRecruitingPreventionChronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary1
Not AvailableRecruitingTreatmentCritical Care / Fluid Shifts1
Not AvailableRecruitingTreatmentHeart Failure, Unspecified1
Not AvailableTerminatedDiagnosticAcute Decompensated Heart Failure (ADHF)1
Not AvailableTerminatedTreatmentAcute Decompensated Heart Failure (ADHF) / Cardiac Failure / Heart Failure, Unspecified1
Not AvailableTerminatedTreatmentBrain Swelling / Dehydration1
Not AvailableTerminatedTreatmentObesity-induced Hyperfiltration1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusTreatmentHypernatremia / Respiratory Failure / Volume Overload1
Not AvailableUnknown StatusTreatmentIntra-Abdominal Hypertension1
Not AvailableWithdrawnPreventionRenal Impairment After Cardiac Surgery1
Not AvailableWithdrawnTreatmentAnemia Treatment Among Patients Suffering From Left Ventricular Systolic Dysfunction1
Not AvailableWithdrawnTreatmentCongestive Heart Failure (CHF)2
Not AvailableWithdrawnTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Organon usa inc
  • Smith and nephew solopak div smith and nephew
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Wockhardt ltd
  • Wyeth ayerst laboratories
  • Sanofi aventis us llc
  • Roxane laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Dava pharmaceuticals inc
  • Excellium pharmaceutical inc
  • International medication systems ltd
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kalapharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Superpharm corp
  • Vintage pharmaceuticals inc
  • County line pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
TabletOral20 mg
TabletOral40 mg
Kit
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous100 mg/10mL
InjectionIntramuscular; Intravenous20 mg/2mL
InjectionIntramuscular; Intravenous40 mg/4mL
InjectionIntravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
SolutionOral10 mg/mL
SolutionOral40 mg/4mL
SolutionOral40 mg/5mL
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
LiquidIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous20 mg
SolutionIntravenous250 mg
LiquidIntravenous250 mg
SolutionIntravenous10 mg
TabletOral80 mg
LiquidOral10 mg
SolutionOral10 mg
LiquidIntramuscular; Intravenous20 mg
TabletOral500 mg
LiquidIntravenous10 mg
Prices
Unit descriptionCostUnit
Hydro 40 40% Foam 150 gm Can182.52USD can
Hydro 40 40% Foam 70 gm Can148.99USD can
Furosemide 10 mg/ml Solution 60ml Bottle17.99USD bottle
Furosemide 10 mg/ml Solution 120ml Bottle15.98USD bottle
Furosemide powder3.51USD g
Lasix Special 500 mg Tablet3.25USD tablet
Urex 1 gm tablet2.47USD tablet
Furosemide 10 mg/ml cartrg1.45USD ml
Lasix 80 mg tablet1.0USD tablet
Furosemide 10 mg/ml Solution0.9USD ml
Furosemide 10 mg/ml0.75USD ml
Lasix 40 mg tablet0.53USD tablet
Furosemide 80 mg tablet0.45USD tablet
Lasix 20 mg tablet0.42USD tablet
Lasix 10 mg/ml Solution0.3USD ml
CVS Pharmacy diuretic 50 mg softgel0.17USD softgel capsule
Furosemide 40 mg tablet0.16USD tablet
Furosemide 20 mg tablet0.14USD tablet
Apo-Furosemide 80 mg Tablet0.13USD tablet
Novo-Semide 80 mg Tablet0.13USD tablet
Nat herbal diuretic tablet sa0.1USD tablet
Apo-Furosemide 40 mg Tablet0.07USD tablet
Natural herbal diuretic tablet0.07USD tablet
Novo-Semide 40 mg Tablet0.07USD tablet
Apo-Furosemide 20 mg Tablet0.05USD tablet
Novo-Semide 20 mg Tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)206U.S. Patent 3,058,882.
water solubility73.1 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.03SANGSTER (1993)
logS-3.66ADME Research, USCD
Caco2 permeability-6.5ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.118 mg/mLALOGPS
logP2.71ALOGPS
logP1.75ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.25ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area122.63 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity77.47 m3·mol-1ChemAxon
Polarizability30.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier-0.8833
Caco-2 permeable-0.6436
P-glycoprotein substrateNon-substrate0.8775
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.6878
CYP450 2D6 substrateNon-substrate0.8351
CYP450 3A4 substrateNon-substrate0.6789
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9602
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6469
BiodegradationNot ready biodegradable0.9881
Rat acute toxicity2.1362 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9342
hERG inhibition (predictor II)Non-inhibitor0.8525
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-03dr-0090000000-da505a3f09285d049f34
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0f89-2190000000-53c91100e89c81f0fa30
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-01ox-9660000000-83d8486cbca0dd3487c9
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-f3a3dcb92cfcdff9f7dc
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0019000000-946089b12d2ab6fd05a4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-04af1dec204d462d4bc4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1090000000-1af70d23e1a0ebaa0878
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9770000000-0c5cd578b5b69a1a61d4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9800000000-3303b20f9b23e24ae312
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9400000000-23cfec716ac8fbcb092f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0019000000-e73aa1d969ab4255732b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-33053544119c01ac6b45
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1090000000-7029ab63efa73a3ff88d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9670000000-4bad8928bbcfc85f431f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9800000000-2193e38e314f2b18be26
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9600000000-e703f7ab6221182df156
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-f3645e993869ff3886ba
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-18400153a811f7100a2f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0f79-0090000000-7e491b92dab050fb81c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-8e41d38fe799d96230a6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-cfec4a54171c58245919
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ug0-0193000000-b55039ca13cbc3acd9a8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0290000000-1f1017fe4370d9541f6d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-9110000000-505f1e781d384073f688
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001j-9000000000-cd886e0521fb4d1bdc82
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8a69e99643ee37bc1883
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-f7ac3c9eea39ed725cfc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8a294fd51a34073aa4a1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-b16e204dec9ae7938d40
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f8a-9220000000-3bde836fe7e67c9b8755
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-9025c2261c96ca3aa551
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8d05f828403d0fe7cac4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-3cd4f8015eb5fafacacb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-34937031271e62c39c1f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-40e9966d335f71aedb96
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0290000000-586707fb0116e8b61643
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-9000000000-f6727b05eb8ee02a6e7c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-51662bec1d461d0f0a5a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-8eea44e0dd27bb59939d
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Aminobenzenesulfonamides
Alternative Parents
4-halobenzoic acids / Aminobenzoic acids / Halobenzoic acids / Benzenesulfonyl compounds / Benzoic acids / Aniline and substituted anilines / Benzoyl derivatives / Phenylalkylamines / Secondary alkylarylamines / Chlorobenzenes
show 15 more
Substituents
Aminobenzenesulfonamide / 4-halobenzoic acid or derivatives / Aminobenzoic acid / Aminobenzoic acid or derivatives / Halobenzoic acid or derivatives / 4-halobenzoic acid / Halobenzoic acid / Benzenesulfonyl group / Benzoic acid / Benzoic acid or derivatives
show 37 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, furans, chlorobenzoic acid (CHEBI:47426)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Brater DC: Pharmacology of diuretics. Am J Med Sci. 2000 Jan;319(1):38-50. [PubMed:10653443]
  2. Davies DL, Wilson GM: Diuretics: mechanism of action and clinical application. Drugs. 1975;9(3):178-226. [PubMed:1092541]
  3. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name
PGD
Uniprot ID
P52209
Uniprot Name
6-phosphogluconate dehydrogenase, decarboxylating
Molecular Weight
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kim GH, Na KY, Kim SY, Joo KW, Oh YK, Chae SW, Endou H, Han JS: Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant. 2003 Aug;18(8):1505-11. [PubMed:12897087]
  2. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087]
  3. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961]
  4. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, a...
Gene Name
SLCO2A1
Uniprot ID
Q92959
Uniprot Name
Solute carrier organic anion transporter family member 2A1
Molecular Weight
70043.33 Da
References
  1. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34